Galectin Therapeutics Inc. (GALT)

[Tekterra]

When you put it that way with a double blind study, they wouldn't know what's going on until trail end and data is compared. In this case, it's make or break come year end. Another failure could be ugly and out of money again. What about their skin studies?

Apparently companies looking to acquire NASH developmental drugs made a pass on Galectin and ended up choosing others like CNAT or Tobria.

There is obviously some degree of success for further study. Don't you think GR-MD-02 would likely be part of a combination therapy? The way I see is that it's got good safety record, and even if it isn't that effective, it's still valuable in slowing or preventing further progression of liver damage.

Who else is targeting the late stage NASH that can save lives? If it is capable of just preventing the condition from getting worst, it's still very valuable. Not necessarily having to be able to reverse the problem.

I am not recommending to go all in on GALT, but I think they still have something worth awhile.